Multiple Endocrine Neoplasia Type 2a

THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a daily injectable GLP-1 medicine for people living with Type 2 diabetes. Liraglutide , the generic for Victoza, is similar to semaglutide, the active ingredient in the popular weight-loss drug Ozempic . The FDA supports the development of generic drugs, such as GLP-1s, by funding research and informing industry through guidance, Dr. Iilun Murphy , director of the FDA’s Office of Generic Drugs, said. “Generic drugs provide additional treatment options which are generally more affordable for patients,” she said in a statement released Dec. 23, 2024. “Today’s approval underscores the FDA’s continued commitment to advancing patient access to safe, effective and high-quality generic drug products.” Last month, the agency approved the first generic version in this class of medications with the green lighting of a generic version of Byetta (exenatide) . Experts hope the new approvals will help prevent shortages triggered by demand for injectable weight loss and type 2 diabetes drugs, including semaglutide (Ozempic, Wegovy ) and tirzepatide ( Mounjaro , Zepbound ). Liraglutide is expected to expand access for people managing type 2 diabetes , which affects more than 38 million Americans, according to federal health data. Type 2 diabetes is a chronic condition that occurs when the body does not use insulin well and cannot keep blood sugar at normal levels. It is usually diagnosed in adults, but has been increasingly diagnosed in children and teens. Liraglutide improves blood sugar levels by creating similar effects in the body as GLP-1 in the pancreas, which is often found in insufficient levels in those with type 2 diabetes. The prescribing information for the generic version includes a warning about the increased risk of thyroid C-cell tumors. For this reason, patients who have had, or have family members who have ever had medullary thyroid carcinoma should not use liraglutide, nor should those who have an endocrine system condition called multiple endocrine neoplasia syndrome type 2. The most common side effects reported in the clinical trials for liraglutide injection include nausea, diarrhea, vomiting, decreased appetite, dyspepsia and constipation. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a daily injectable GLP-1 medicine for people living with Type 2 diabetes . Liraglutide , the generic for Victoza , is similar to semaglutide, the active ingredient in the popular weight-loss drug Ozempic . The FDA supports the development of generic drugs, such as GLP-1s, by funding research and informing industry through guidance, Dr. Iilun Murphy , director of the FDA’s Office of Generic Drugs, said. “Generic drugs provide additional treatment options which are generally more affordable for patients,” she said in a statement released Dec. 23, 2024. “Today’s approval underscores the FDA’s continued commitment to advancing patient access to safe, effective and high-quality generic drug products.” Last month, the agency approved the first generic version in this class of medications with the green lighting of a generic version of Byetta (exenatide) . Experts hope the new approvals will help prevent shortages triggered by demand for injectable weight loss and type 2 diabetes drugs, including semaglutide (Ozempic, Wegovy ) and tirzepatide ( Mounjaro , Zepbound ). Liraglutide is expected to expand access for people managing type 2 diabetes , which affects more than 38 million Americans, according to federal health data. Type 2 diabetes is a chronic condition that occurs when the body does not use insulin well and cannot keep blood sugar at normal levels. It is usually diagnosed in adults, but has been increasingly diagnosed in children and teens. Liraglutide improves blood sugar levels by creating similar effects in the body as GLP-1 in the pancreas, which is often found in insufficient levels in those with type 2 diabetes. The prescribing information for the generic version includes a warning about the increased risk of thyroid C-cell tumors. For this reason, patients who have had, or have family members who have ever had medullary thyroid carcinoma should not use liraglutide, nor should those who have an endocrine system condition called multiple endocrine neoplasia syndrome type 2. The most common side effects reported in the clinical trials for liraglutide injection include nausea, diarrhea, vomiting, decreased appetite, dyspepsia and constipation. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

SILVER SPRING, MD, USA I December 23, 2024 I Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes as an adjunct to diet and exercise. The FDA approved the first generic in this class of medications last month with the approval of a generic referencing Byetta (exenatide). Liraglutide injection and certain other GLP-1 medications are currently in shortage . The FDA prioritizes assessment of generic drug applications for drugs in shortage to help improve patient access to these medications. “The FDA supports development of complex generic drugs, such as GLP-1s, by funding research and informing industry through guidance as part of our ongoing efforts to increase access to needed medications,” said Iilun Murphy, M.D., director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research. “Generic drugs provide additional treatment options which are generally more affordable for patients. Today’s approval underscores the FDA’s continued commitment to advancing patient access to safe, effective and high-quality generic drug products.” Type 2 diabetes is a chronic condition that occurs when the body does not use insulin well and cannot keep blood sugar at normal levels. It develops over many years and is usually diagnosed in adults, but has been increasingly diagnosed in children, teens and young adults. Liraglutide improves blood sugar levels by creating similar effects in the body as GLP-1 in the pancreas, which is often found in insufficient levels in type 2 diabetes patients. According to the Centers for Disease Control and Prevention, more than 38 million Americans have diabetes, and 90% to 95% of those individuals have type 2 diabetes. The prescribing information for the generic liraglutide injection approved today includes a Boxed Warning to advise health care professionals and patients about the increased risk of thyroid C-cell tumors. For this reason, patients who have had, or have family members who have ever had medullary thyroid carcinoma should not use liraglutide, nor should patients who have an endocrine system condition called multiple endocrine neoplasia syndrome type 2. In addition, people who have a prior serious hypersensitivity reaction to liraglutide or any of the product components should not use liraglutide. Liraglutide also carries warnings about pancreatitis, liraglutide pen sharing, hypoglycemia when used in conjunction with certain other drugs known to cause hypoglycemia including insulin and sulfonylurea, renal impairment or kidney failure, hypersensitivity and acute gallbladder disease. The most common side effects reported in the clinical trials for liraglutide injection include nausea, diarrhea, vomiting, decreased appetite, dyspepsia and constipation. Addressing the challenges related to developing generics and promoting more generic competition is a key part of the FDA’s Drug Competition Action Plan and the agency’s efforts to help increase patient access to medicines. The development of complex drug products such as liraglutide can be more difficult due to their complex active ingredient, formulation or mode of delivery. As a result, many complex drugs lack generic competition. To address this issue and facilitate timely development and approval of needed medications, particularly complex products, the FDA works to clarify regulatory expectations for applicants early in the development process, including through guidance for industry and the pre-ANDA program . These efforts make it more feasible for manufacturers to develop generic drugs and can enhance patient access to treatment by helping make these products more available, allowing patients in the United States to obtain the medicines they need. The FDA granted the approval of generic liraglutide injection to Hikma Pharmaceuticals USA Inc. Please contact the manufacturer for information about the medicine’s availability. Additional Resources: The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products. SOURCE: U.S. Food and Drug Administration